These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32019876)

  • 1. Pharmacodynamics of natalizumab extended interval dosing in MS.
    Zhovtis Ryerson L; Li X; Goldberg JD; Hoyt T; Christensen A; Metzger RR; Kister I; Foley J
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32019876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of natalizumab extended interval dosing.
    Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
    Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    Chisari CG; Grimaldi LM; Salemi G; Ragonese P; Iaffaldano P; Bonavita S; Sparaco M; Rovaris M; D'Arma A; Lugaresi A; Ferrò MT; Grossi P; Di Sapio A; Cocco E; Granella F; Curti E; Lepore V; Trojano M; Patti F;
    J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1297-1303. PubMed ID: 33055141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
    Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
    Front Immunol; 2021; 12():614715. PubMed ID: 33841397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.
    Ruggieri S; Ianniello A; Copetti M; Altieri M; Buscarinu MC; Centonze D; Cortese A; De Giglio L; Fantozzi R; Gasperini C; Grimaldi LME; Landi D; Marfia GA; Mirabella M; Nistri R; Nociti V; Oddo O; Romano S; Salemi G; Tortorella C; Pozzilli C; Petracca M
    Neurotherapeutics; 2024 Apr; 21(3):e00338. PubMed ID: 38413275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
    Chang I; Muralidharan KK; Campbell N; Ho PR
    J Clin Pharmacol; 2021 Mar; 61(3):339-348. PubMed ID: 32949472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.
    Gelissen LMY; Loveless S; Toorop AA; Howlett J; Loeff FC; Rispens T; Killestein J; Tallantyre EC; van Kempen ZLE
    Mult Scler Relat Disord; 2024 Oct; 90():105796. PubMed ID: 39096666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
    Bringeland GH; Blaser N; Myhr KM; Vedeler CA; Gavasso S
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
    Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
    Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
    Scarpazza C; De Rossi N; Tabiadon G; Turrini MV; Gerevini S; Capra R
    Neurol Sci; 2019 Oct; 40(10):2119-2124. PubMed ID: 31175467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4
    Soldati S; Bär A; Vladymyrov M; Glavin D; McGrath JL; Gosselet F; Nishihara H; Goelz S; Engelhardt B
    J Neuroinflammation; 2023 May; 20(1):123. PubMed ID: 37221552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    Toorop AA; Wessels MHJ; Gelissen LMY; Hoitsma E; Zeinstra EMPE; van Rooij LC; van Munster CEP; Vennegoor A; Mostert JP; Wokke BHA; Kalkers NF; Hoogervorst ELJ; van Eijk JJJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige LGF; Kloosterziel ME; Arnoldus EPJ; van Dijk GW; Bouvy WH; Strijbis EMM; van Oosten BW; de Jong BA; Lissenberg-Witte BI; Rispens T; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    J Neurol Sci; 2024 Jul; 462():123102. PubMed ID: 38925067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer of natalizumab into breast milk in a mother with multiple sclerosis.
    Baker TE; Cooper SD; Kessler L; Hale TW
    J Hum Lact; 2015 May; 31(2):233-6. PubMed ID: 25586712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.